Sarepta Therapeutics (SRPT) Tops Q2 EPS by 92c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), $0.92 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $261.2 million versus the consensus estimate of $259.79 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• CIGNA (CI) PT Raised to $370 at Piper Sandler
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'